Your browser doesn't support javascript.
loading
Addressing financial toxicity in cancer treatment-An opportunity for the 340B drug pricing program.
Faraj, Kassem S; Caram, Megan E V; Shahinian, Vahakn B; Hollenbeck, Brent K.
Affiliation
  • Faraj KS; Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, Michigan, USA.
  • Caram MEV; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Shahinian VB; VA Health Services Research and Development, Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.
  • Hollenbeck BK; Division of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Cancer ; 130(18): 3077-3081, 2024 Sep 15.
Article in En | MEDLINE | ID: mdl-38804732
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Costs / Neoplasms / Antineoplastic Agents Limits: Humans Country/Region as subject: America do norte Language: En Journal: Cancer Year: 2024 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Costs / Neoplasms / Antineoplastic Agents Limits: Humans Country/Region as subject: America do norte Language: En Journal: Cancer Year: 2024 Document type: Article Affiliation country: Country of publication: